Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults.
OBJECTIVE
To determine whether older adults with high plasma carboxymethyl-lysine (CML), an advanced glycation end product, are at higher risk of all-cause and cardiovascular disease (CVD) mortality.


METHODS
Prospective cohort study.


METHODS
Population-based sample of adults aged 65 and older residing in Tuscany, Italy.


METHODS
One thousand thirteen adults participating in the Invecchiare in Chianti study.


METHODS
Anthropometric measures, plasma CML, fasting plasma total, high-density and low-density lipoprotein cholesterol, triglycerides, glucose, creatinine. Clinical measures: medical assessment, diabetes mellitus, hypertension, coronary heart disease, heart failure, stroke, cancer. Vital status measures: death certificates and causes of death according to the International Classification of Diseases. Survival methods were used to examine the relationship between plasma CML and all-cause and CVD mortality, adjusting for potential confounders.


RESULTS
During 6 years of follow-up, 227 (22.4%) adults died, of whom 105 died with CVD. Adults with plasma CML in the highest tertile had greater all-cause (hazard ratio (HR)=1.84, 95% confidence interval) CI)=1.30-2.60, P<.001) and CVD (HR=2.11, 95% CI=1.27-3.49, P=.003) mortality than those in the lower two tertiles after adjusting for potential confounders. In adults without diabetes mellitus, those with plasma CML in the highest tertile had greater all-cause (HR=1.68, 95% CI=1.15-2.44, P=.006) and CVD (HR=1.74, 95% CI=1.00-3.01, P=.05) mortality than those in the lower two tertiles after adjusting for potential confounders.


CONCLUSIONS
Older adults with high plasma CML are at higher risk of all-cause and CVD mortality.
Semba
Richard D
RD
Department of Ophthalmology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. rdsemba@jhmi.edu
Bandinelli
Stefania
S
Sun
Kai
K
Guralnik
Jack M
JM
Ferrucci
Luigi
L
D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000097:blood* / Q000401:mortality*; D002423:Cause of Death; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D008297:Male; D011446:Prospective Studies
D017127:Glycation End Products, Advanced; C048496:N(6)-carboxymethyllysine; D008239:Lysine
J Clin Invest. 1997 Feb 1;99(3):457-68
9022079
J Am Geriatr Soc. 2000 Dec;48(12):1618-25
11129752
Ann Intern Med. 1999 Mar 16;130(6):461-70
10075613
Diabetologia. 2004 Aug;47(8):1376-9
15258735
Curr Diab Rep. 2007 Jun;7(3):235-41
17547841
Clin Chem. 1972 Jun;18(6):499-502
4337382
J Am Geriatr Soc. 2005 Dec;53(12):2159-64
16398902
Biochemistry. 1995 Aug 29;34(34):10872-8
7662668
J Biol Chem. 1999 Oct 29;274(44):31740-9
10531386
Diabetes Care. 2003 Nov;26(11):3160-7
14578255
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15596-601
12429856
Diabetologia. 2007 Jul;50(7):1409-17
17479244
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Am J Clin Nutr. 2007 May;85(5):1236-43
17490958
Clin Chem Lab Med. 2005;43(5):503-11
15899672
Am J Kidney Dis. 2006 Feb;47(2):294-300
16431258
Cardiovasc Res. 2004 Sep 1;63(4):582-92
15306213
Curr Med Chem. 2004 Oct;11(20):2767-84
15544475
J Am Diet Assoc. 2004 Aug;104(8):1287-91
15281050
J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):427-33
17452738
Obes Res. 2001 Nov;9 Suppl 4:228S-233S
11707546
Arch Intern Med. 2003 Jul 14;163(13):1549-54
12860577
Am J Physiol Renal Physiol. 2005 Oct;289(4):F645-59
16159899
J Card Fail. 2005 Apr;11(3):191-5
15812746
Circulation. 2001 Sep 25;104(13):1464-70
11571237
Diabetes Care. 2006 Jan;29 Suppl 1:S43-8
16373932
Am J Hypertens. 2009 Jan;22(1):74-9
19023277
Am J Pathol. 2007 Jun;170(6):1893-902
17525257